CD70-targeted cancer theranostics: Progress and challenges

Area of Science:

• Oncology
• Molecular Imaging
• Immunotherapy

Background:

• CD70 is a tumor antigen overexpressed in clear cell renal cell carcinoma (ccRCC), nasopharyngeal carcinoma, and lymphoma.
• CD70 expression is minimal in healthy tissues, making it a specific target.
• CD70 is a promising biomarker for advanced cancer diagnostics and therapeutics.

Purpose of the Study:

• To evaluate CD70-targeted immunoPET imaging for diagnosing ccRCC metastases.
• To assess the utility of CD70 imaging in patient selection for immunotherapies.
• To explore the potential of CD70-targeted radiotheranostics.

Main Methods:

• Development and application of single-domain antibody-derived tracers ([18F]RCCB6, [68Ga]Ga-NOTA-RCCB6) for immunoPET imaging.
• Utilizing CD70 expression levels for patient stratification in targeted therapies.
• Investigating radiolabeled tracers for simultaneous diagnosis and treatment (radiotheranostics).

Main Results:

• ImmunoPET imaging with CD70 tracers demonstrated high diagnostic precision for ccRCC metastases.
• CD70 imaging accurately identified common and rare metastatic sites, improving staging.
• CD70 expression levels effectively stratified patients for CAR-T cell and ADC therapies.

Conclusions:

• CD70-targeted immunoPET imaging enhances diagnostic accuracy and staging for ccRCC.
• CD70 imaging is crucial for optimizing patient selection and monitoring response to immunotherapies.
• Radiotheranostic approaches targeting CD70 offer new avenues for precise cancer management.